Mecanismes de resposta a la inducció per hipòxia Bibliografia
127
7. BIBLIOGRAFIA 1. Boyle, P. and Ferlay, J. (2005). Cancer incidence and mortality in Europe, 2004. Ann Oncol 16,
481-488.
2. Cahill, D. P., Kinzler, K. W., Vogelstein, B., and Lengauer, C. (1999). Genetic instability and
darwinian selection in tumours. Trends Cell Biol 9, M57-M60.
3. Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
4. Skobe, M. and Fusenig, N. E. (1998). Tumorigenic conversion of immortal human keratinocytes
through stromal cell activation. Proc Natl Acad Sci U S A 95, 1050-1055.
5. Soussi, T. and Lozano, G. (2005). p53 mutation heterogeneity in cancer. Biochem Biophys.Res
Commun. 331, 834-842.
6. Kirkin, V., Joos, S., and Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis.
Biochim.Biophys.Acta 1644, 229-249.
7. Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and Gonzalez-Baron, M.
(2004). PI3K/Akt signalling pathway and cancer. Cancer Treat.Rev 30, 193-204.
8. Shay, J. W. and Bacchetti, S. (1997). A survey of telomerase activity in human cancer. Eur J
Cancer 33, 787-791.
9. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. (1997).
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
Am J Pathol 150, 815-821.
10. Folkman, J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol 3, 65-71.
11. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer
Inst 82, 4-6.
12. Rofstad, E. K. and Danielsen, T. (1999). Hypoxia-induced metastasis of human melanoma cells:
involvement of vascular endothelial growth factor-mediated angiogenesis. Br.J.Cancer 80, 1697-
1707.
13. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. (1995). Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J
Pathol 146, 1029-1039.
14. Fox, S. B. (1997). Tumour angiogenesis and prognosis. Histopathology 30, 294-301.
15. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of
angiogenesis. Proc Natl Acad Sci U S A 91, 4082-4085.
16. Mori, S., Ueda, T., Kuratsu, S., Hosono, N., Izawa, K., and Uchida, A. (1995). Suppression of
pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61,
148-152.
17. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and
Steeg, P. S. (1994). Transfection of thrombospondin 1 complementary DNA into a human breast
carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer
Res 54, 6504-6511.
18. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R.,
Olsen, B. R., and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and
tumor growth. Cell 88, 277-285.
19. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks,
W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A., Hajjar, K. A.,
Manova, K., Benezra, R., and Rafii, S. (2001). Impaired recruitment of bone-marrow-derived
Mecanismes de resposta a la inducció per hipòxia Bibliografia
128
endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7,
1194-1201.
20. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., and Seftor, R. E. B. Vasculogenic mimicry and tumour-
cell plasticity: lessons from melanoma. Nat.Med. 3, 411-421. 2003.
Ref Type: Generic
21. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth.
Cardiovasc.Res 49, 507-521.
22. Bergersm, G. and Benjamin, L. E. Tumorigenesis and the angiognic switch. Nat.Med. 3, 401-410.
2003.
Ref Type: Generic
23. Ausprunk, D. H. and Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed
and newly formed blood vessels during tumor angiogenesis. Microvasc.Res 14, 53-65.
24. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002).
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160,
985-1000.
25. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K.
(1998). Regulation of transport pathways in tumor vessels: role of tumor type and
microenvironment. Proc Natl Acad Sci U S A 95, 4607-4612.
26. Jakeman, L. B., Armanini, M., Phillips, H. S., and Ferrara, N. (1993). Developmental expression of
binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role
for this protein in vasculogenesis and angiogenesis. Endocrinology 133, 848-859.
27. Senger, D. R., Van de, W. L., Brown, L. F., Nagy, J. A., Yeo, K. T., Yeo, T. K., Berse, B., Jackman,
R. W., Dvorak, A. M., and Dvorak, H. F. (1993). Vascular permeability factor (VPF, VEGF) in tumor
biology. Cancer Metastasis Rev 12, 303-324.
28. Achen, M. G. and Stacker, S. A. (1998). The vascular endothelial growth factor family; proteins
which guide the development of the vasculature. Int J Exp Pathol 79, 255-265.
29. Tammela, T., Enholm, B., Alitalo, K., and Paavonen, K. (2005). The biology of vascular endothelial
growth factors. Cardiovascular Research 65, 550-563.
30. Korhonen, J., Partanen, J., Armstrong, E., Vaahtokari, A., Elenius, K., Jalkanen, M., and Alitalo, K.
(1992). Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during
neovascularization. Blood 80, 2548-2555.
31. Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J.,
Radziejewski, C., Maisonpierre, P. C., and Yancopoulos, G. D. (1996). Isolation of angiopoietin-1, a
ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169.
32. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C.,
Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., and
Yancopoulos, G. D. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
angiogenesis. Science 277, 55-60.
33. Valenzuela, D. M., Griffiths, J. A., Rojas, J., Aldrich, T. H., Jones, P. F., Zhou, H., McClain, J.,
Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Huang, T., Papadopoulos, N., Maisonpierre, P. C.,
Davis, S., and Yancopoulos, G. D. (1999). Angiopoietins 3 and 4: diverging gene counterparts in
mice and humans. Proc Natl Acad Sci U S A 96, 1904-1909.
34. Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C.,
and Sessa, W. C. (2000). Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin
Pathway. J.Biol.Chem. 275, 9102-9105.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
129
35. Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., O'Brien-Jenkins, A., Randall,
T. C., Rubin, S. C., and Coukos, G. (2003). Tumor-derived vascular endothelial growth factor up-
regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting
angiogenesis in ovarian cancer. Cancer Res 63, 3403-3412.
36. Xu, Y., Liu, Y. J., and Yu, Q. (2004). Angiopoietin-3 inhibits pulmonary metastasis by inhibiting
tumor angiogenesis. Cancer Res 64, 6119-6126.
37. Yamakawa, M., Liu, L. X., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Kuriyama, T.,
Cheng, S. H., Gregory, R. J., and Jiang, C. (2003). Hypoxia-inducible factor-1 mediates activation of
cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93, 664-673.
38. Friesel, R. E. and Maciag, T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth
factor signal transduction. FASEB J 9, 919-925.
39. Schreiber, A. B., Winkler, M. E., and Derynck, R. (1986). Transforming growth factor-alpha: a more
potent angiogenic mediator than epidermal growth factor. Science 232, 1250-1253.
40. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N.
(1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature
329, 630-632.
41. Moghaddam A. Thymidine phosphorylase/platelet endothelial cell derived growth factor: an
angogenic enzyme. Tumor Angiogenesis, Oxford University Press , 251-260. 1997.
Ref Type: Generic
42. Hu, G., Riordan, J. F., and Vallee, B. L. (1994). Angiogenin promotes invasiveness of cultured
endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A 91,
12096-12100.
43. Desbaillets, I., Diserens, A. C., Tribolet, N., Hamou, M. F., and Van Meir, E. G. (1997). Upregulation
of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation,
chemotaxis, and angiogenesis. J Exp Med 186, 1201-1212.
44. Gullino, P. M. (1995). Prostaglandins and gangliosides of tumor microenvironment: their role in
angiogenesis. Acta Oncol 34, 439-441.
45. Kull, F. C., Jr., Brent, D. A., Parikh, I., and Cuatrecasas, P. (1987). Chemical identification of a
tumor-derived angiogenic factor. Science 236, 843-845.
46. Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcí, a-Cardeñ, a, G.,
Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P.
J., and Flores-Riveros, J. R. (1998). Biological Action of Leptin as an Angiogenic Factor. Science
281, 1683-1686.
47. Nyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. Cancer Res 65,
3967-3979.
48. Lartigau, E., Le Ridant, A. M., Lambin, P., Weeger, P., Martin, L., Sigal, R., Lusinchi, A., Luboinski,
B., Eschwege, F., and Guichard, M. (1993). Oxygenation of head and neck tumors. Cancer 71,
2319-2325.
49. Lartigau, E., Randrianarivelo, H., Avril, M. F., Margulis, A., Spatz, A., Eschwege, F., and Guichard,
M. (1997). Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 7, 400-406.
50. Zygmunt, A., Tedesco, V. C., Udho, E., and Krucher, N. A. (2002). Hypoxia stimulates p16
expression and association with cdk4. Exp.Cell Res 278, 53-60.
51. Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., and Dang, C. V. (2001).
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. J.Biol.Chem. 276, 7919-
7926.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
130
52. To, K. K., Koshiji, M., Hammer, S., and Huang, L. E. (2005). Genetic instability: the dark side of the
hypoxic response. Cell Cycle 4, 881-882.
53. Dong, Z., Wang, J. Z., Yu, F., and Venkatachalam, M. A. (2003). Apoptosis-Resistance of Hypoxic
Cells: Multiple Factors Involved and a Role for IAP-2. Am J Pathol 163, 663-671.
54. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and
Dewhirst, M. W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in
human soft tissue sarcoma. Cancer Res 56, 941-943.
55. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by
hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
56. Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., and Gallick, G.
E. (2005). HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional
complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and
prostate carcinomas. Oncogene 24, 3110-3120.
57. Shie, J. L., Wu, G., Wu, J., Liu, F. F., Laham, R. J., Oettgen, P., and Li, J. (2004). RTEF-1, a novel
transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol
Chem. 279, 25010-25016.
58. Mizukami, Y., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., and Chung, D. C. (2004). Hypoxia-
Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in
Colon Cancer. Cancer Res 64, 1765-1772.
59. White, F. C., Carroll, S. M., and Kamps, M. P. (1995). VEGF mRNA is reversibly stabilized by
hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors
12, 289-301.
60. Gerber, H. P., Condorelli, F., Park, J., and Ferrara, N. (1997). Differential Transcriptional Regulation
of the Two Vascular Endothelial Growth Factor Receptor Genes. Flt-1, BUT NOT Flk-1/KDR, IS UP-
REGULATED BY HYPOXIA. J.Biol.Chem. 272, 23659-23667.
61. Ozawa, K., Tsukamoto, Y., Hori, O., Kitao, Y., Yanagi, H., Stern, D. M., and Ogawa, S. (2001).
Regulation of Tumor Angiogenesis by Oxygen-regulated Protein 150, an Inducible Endoplasmic
Reticulum Chaperone. Cancer Res 61, 4206-4213.
62. Abdulmalek, K., Ashur, F., Ezer, N., Ye, F., Magder, S., and Hussain, S. N. (2001). Differential
expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am.J.Physiol
Lung Cell Mol Physiol 281, L582-L590.
63. Hartmann, A., Kunz, M., Kostlin, S., Gillitzer, R., Toksoy, A., Brocker, E. B., and Klein, C. E. (1999).
Hypoxia-induced Up-Regulation of Angiogenin in Human Malignant Melanoma. Cancer Res 59,
1578-1583.
64. Griffiths, L., Dachs, G. U., Bicknell, R., Harris, A. L., and Stratford, I. J. (1997). The influence of
oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine
phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57, 570-572.
65. Kitazono, M., Takebayashi, Y., Ishitsuka, K., Takao, S., Tani, A., Furukawa, T., Miyadera, K.,
Yamada, Y., Aikou, T., and Akiyama, S. (1998). Prevention of hypoxia-induced apoptosis by the
angiogenic factor thymidine phosphorylase. Biochem Biophys.Res Commun. 253, 797-803.
66. Chen, E. Y., Mazure, N. M., Cooper, J. A., and Giaccia, A. J. (2001). Hypoxia activates a platelet-
derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen
synthase kinase-3 inactivation. Cancer Res 61, 2429-2433.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
131
67. Graham, C. H., Forsdike, J., Fitzgerald, C. J., and Macdonald-Goodfellow, S. (1999). Hypoxia-
mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor
expression. Int J Cancer 80, 617-623.
68. Ridgway, P. F., Ziprin, P., Alkhamesi, N., Paraskeva, P. A., Peck, D. H., and Darzi, A. W. (2005).
Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg.Res 124, 180-
186.
69. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H. J., Benedict, W., and Bouck, N. P.
(1999). Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis. Science 285, 245-
248.
70. Wu, P., Yonekura, H., Li, H., Nozaki, I., Tomono, Y., Naito, I., Ninomiya, Y., and Yamamoto, H.
(2001). Hypoxia down-regulates endostatin production by human microvascular endothelial cells
and pericytes. Biochem.Biophys.Res Commun. 288, 1149-1154.
71. Cummins, E. P. and Taylor, C. T. (2005). Hypoxia-responsive transcription factors. Pflugers Arch.
450, 363-371.
72. Abate, C., Patel, L., Rauscher, F. J., III, and Curran, T. (1990). Redox regulation of fos and jun
DNA-binding activity in vitro. Science 249, 1157-1161.
73. Ausserer, W. A., Bourrat-Floeck, B., Green, C. J., Laderoute, K. R., and Sutherland, R. M. (1994).
Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 14, 5032-5042.
74. Fantozzi, I., Zhang, S., Platoshyn, O., Remillard, C. V., Cowling, R. T., and Yuan, J. X. J. (2003).
Hypoxia increases AP-1 binding activity by enhancing capacitative Ca2+ entry in human pulmonary
artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 285, L1233-L1245.
75. Laderoute, K. R. (2005). The interaction between HIF-1 and AP-1 transcription factors in response
to low oxygen. Semin Cell Dev Biol 16, 502-513.
76. Marden, N. Y., Fiala-Beer, E., Xiang, S. H., and Murray, M. (2003). Role of activator protein-1 in the
down-regulation of the human CYP2J2 gene in hypoxia. Biochem J 373 , 669-680.
77. May, M. J. and Ghosh, S. (1998). Signal transduction through NF-kappa B. Immunol Today 19 , 80-
88.
78. Koong, A. C., Chen, E. Y., Mivechi, N. F., Denko, N. C., Stambrook, P., and Giaccia, A. J. (1994).
Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and
does not involve MAP kinase (ERK1 or ERK2). Cancer Res 54, 5273-5279.
79. Toledano, M. B. and Leonard, W. J. (1991). Modulation of transcription factor NF-kappa B binding
activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A 88, 4328-4332.
80. Aggarwal, B. B., Takada, Y., Shishodia, S., Gutierrez, A. M., Oommen, O. V., Ichikawa, H., Baba,
Y., and Kumar, A. (2004). Nuclear transcription factor NF-kappa B: role in biology and medicine.
Indian J Exp Biol 42, 341-353.
81. Rahmani, M., Peron, P., Weitzman, J., Bakiri, L., Lardeux, B., and Bernuau, D. (2001). Functional
cooperation between JunD and NF-kappaB in rat hepatocytes. Oncogene 20, 5132-5142.
82. Miki, N., Ikuta, M., and Matsui, T. (2004). Hypoxia-induced Activation of the Retinoic Acid Receptor-
related Orphan Receptor {alpha}4 Gene by an Interaction between Hypoxia-inducible Factor-1 and
Sp1. J.Biol.Chem. 279, 15025-15031.
83. Petrella, B. L., Lohi, J., and Brinckerhoff, C. E. (2005). Identification of membrane type-1 matrix
metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell
carcinoma. Oncogene 24, 1043-1052.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
132
84. Xu, Q., Ji, Y. S., and Schmedtje, J. F., Jr. (2000). Sp1 increases expression of cyclooxygenase-2 in
hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
J Biol Chem. 275, 24583-24589.
85. Lichtlen, P. and Schaffner, W. (2001). The "metal transcription factor" MTF-1: biological facts and
medical implications. Swiss.Med Wkly. 131, 647-652.
86. Cai, L., Satoh, M., Tohyama, C., and Cherian, M. G. (1999). Metallothionein in radiation exposure:
its induction and protective role. Toxicology 132, 85-98.
87. van Lookeren, C. M., Thibodeaux, H., van Bruggen, N., Cairns, B., Gerlai, R., Palmer, J. T.,
Williams, S. P., and Lowe, D. G. (1999). Evidence for a protective role of metallothionein-1 in focal
cerebral ischemia. Proc Natl Acad Sci U S A 96, 12870-12875.
88. Lazo, J. S., Kondo, Y., Dellapiazza, D., Michalska, A. E., Choo, K. H., and Pitt, B. R. (1995).
Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in
metallothionein I and II genes. J Biol Chem. 270, 5506-5510.
89. Murphy, B. J., Andrews, G. K., Bittel, D., Discher, D. J., McCue, J., Green, C. J., Yanovsky, M.,
Giaccia, A., Sutherland, R. M., Laderoute, K. R., and Webster, K. A. (1999). Activation of
metallothionein gene expression by hypoxia involves metal response elements and metal
transcription factor-1. Cancer Res 59, 1315-1322.
90. Murphy, B. J., Sato, B. G., Dalton, T. P., and Laderoute, K. R. (2005). The metal-responsive
transcription factor-1 contributes to HIF-1 activation during hypoxic stress. Biochem Biophys.Res
Commun.
91. McCluggage, W. G., Maxwell, P., Hamilton, P. W., and Jasani, B. (1999). High metallothionein
expression is associated with features predictive of aggressive behaviour in endometrial carcinoma.
Histopathology 34, 51-55.
92. Greijer, A. E., van der, G. P., Kemming, D., Shvarts, A., Semenza, G. L., Meijer, G. A., van de Wiel,
M. A., Belien, J. A., van Diest, P. J., and Van Der, W. E. (2005). Up-regulation of gene expression
by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206, 291-304.
93. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., and Maity, A. (2001). Regulation of glut1 mRNA by
Hypoxia-inducible Factor-1. INTERACTION BETWEEN H-ras AND HYPOXIA. J.Biol.Chem. 276,
9519-9525.
94. Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., and Caro, J.
(2002). Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-
2,6-bisphosphatase-3 (PFKFB3) Gene. ITS POSSIBLE ROLE IN THE WARBURG EFFECT.
J.Biol.Chem. 277, 6183-6187.
95. Acker, T. and Plate, K. H. (2002). A role for hypoxia and hypoxia-inducible transcription factors in
tumor physiology. J.Mol Med. 80, 562-575.
96. Varma, S. and Cohen, H. J. (1997). Co-transactivation of the 3' erythropoietin hypoxia inducible
enhancer by the HIF-1 protein. Blood Cells Mol Dis. 23, 169-176.
97. Liu, L. X., Lu, H., Luo, Y., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Goldberg, M.,
Cheng, S. H., Gregory, R. J., and Jiang, C. (2002). Stabilization of vascular endothelial growth
factor mRNA by hypoxia- inducible factor 1. Biochem.Biophys.Res Commun. 291, 908-914.
98. Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Kawamura, K.,
Hosokawa, M., and Asaka, M. (2001). Constitutive expression of hypoxia-inducible factor-1alpha
renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.
Cancer Res 61, 6548-6554.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
133
99. Wang, G. L., Jiang, B., Rue, E. A., and Semenza, G. L. (1995). Hypoxia-Inducible Factor 1 is a
Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O2 Tension. PNAS 92, 5510-5514.
100. Jiang, B. H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. (1996). Dimerization, DNA binding,
and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 271, 17771-17778.
101. Yang, J., Zhang, L., Erbel, P. J., Gardner, K. H., Ding, K., Garcia, J. A., and Bruick, R. K. (2005).
Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor. J Biol Chem. 280, 36047-
36054.
102. Chapman-Smith, A., Lutwyche, J. K., and Whitelaw, M. L. (2004). Contribution of the Per/Arnt/Sim
(PAS) Domains to DNA Binding by the Basic Helix-Loop-Helix PAS Transcriptional Regulators.
J.Biol.Chem. 279, 5353-5362.
103. Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., and Ratcliffe, P. J. (1997). Activation of
hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem.
272, 11205-11214.
104. Luo, J. C. and Shibuya, M. (2001). A variant of nuclear localization signal of bipartite-type is
required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha).
Oncogene 20, 1435-1444.
105. Hankinson, O. (1995). The aryl hydrocarbon receptor complex. Annu.Rev Pharmacol Toxicol. 35,
307-340.
106. Woods, S. L. and Whitelaw, M. L. (2002). Differential Activities of Murine Single Minded 1 (SIM1)
and SIM2 on a Hypoxic Response Element. CROSS-TALK BETWEEN BASIC HELIX-LOOP-
HELIX/Per-Arnt-Sim HOMOLOGY TRANSCRIPTION FACTORS. J.Biol.Chem. 277, 10236-10243.
107. Lee, K. H., Park, J. W., and Chun, Y. S. (2004). Non-hypoxic transcriptional activation of the aryl
hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha
isoform. Nucl.Acids.Res. 32, 5499-5511.
108. Maltepe, E., Keith, B., Arsham, A. M., Brorson, J. R., and Simon, M. C. (2000). The role of ARNT2
in tumor angiogenesis and the neural response to hypoxia. Biochem.Biophys.Res Commun. 273,
231-238.
109. Liu, C., Goshu, E., Wells, A., and Fan, C. M. (2003). Identification of the downstream targets of
SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J
Biol Chem. 278, 44857-44867.
110. Takahata, S., Sogawa, K., Kobayashi, A., Ema, M., Mimura, J., Ozaki, N., and Fujii-Kuriyama, Y.
(1998). Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-
1a, HLF, and clock. Biochem Biophys.Res Commun. 248, 789-794.
111. Pollenz, R. S., Davarinos, N. A., and Shearer, T. P. (1999). Analysis of aryl hydrocarbon receptor-
mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon
nuclear translocator transcription factor. Mol Pharmacol 56, 1127-1137.
112. Minet, E., Ernest, I., Michel, G., Roland, I., Remacle, J., Raes, M., and Michiels, C. (1999). HIF1A
gene transcription is dependent on a core promoter sequence encompassing activating and
inhibiting sequences located upstream from the transcription initiation site and cis elements located
within the 5'UTR. Biochem Biophys.Res Commun. 261, 534-540.
113. Salceda, S. and Caro, J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly
degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by
hypoxia depends on redox-induced changes. J Biol Chem. 272, 22642-22647.
114. Ohh, M. and Kaelin, W. G., Jr. (1999). The von Hippel-Lindau tumour suppressor protein: new
perspectives. Mol Med.Today 5, 257-263.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
134
115. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000). Mechanism of regulation of the
hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19,
4298-4309.
116. Groulx, I. and Lee, S. (2002). Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-
Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor
Suppressor Protein. Mol.Cell.Biol. 22, 5319.
117. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S.,
and Kaelin, W. G., Jr. (2001). HIFalpha Targeted for VHL-Mediated Destruction by Proline
Hydroxylation: Implications for O2 Sensing. Science 292, 464-468.
118. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. v.,
Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J.
(2001). Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated
Prolyl Hydroxylation. Science 292, 468-472.
119. Hon, W. C., Wilson, M. I., Harlos, K., Claridge, T. D., Schofield, C. J., Pugh, C. W., Maxwell, P. H.,
Ratcliffe, P. J., Stuart, D. I., and Jones, E. Y. (2002). Structural basis for the recognition of
hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978.
120. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001). Independent
function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl
hydroxylation. EMBO J. 20, 5197-5206.
121. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji,
M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P.,
Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2001).
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by
prolyl hydroxylation. Cell 107, 43-54.
122. McNeill, L. A., Hewitson, K. S., Gleadle, J. M., Horsfall, L. E., Oldham, N. J., Maxwell, P. H., Pugh,
C. W., Ratcliffe, P. J., and Schofield, C. J. (2002). The use of dioxygen by HIF prolyl hydroxylase
(PHD1). Bioorg.Med.Chem.Lett. 12, 1547-1550.
123. Huang, J., Zhao, Q., Mooney, S. M., and Lee, F. S. (2002). Sequence determinants in hypoxia-
inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.
J.Biol.Chem. 277, 39792-39800.
124. Kageyama, Y., Koshiji, M., To, K. K. W., Tian, Y. M., Ratcliffe, P. J., and Huang, L. E. (2004). Leu-
574 of human HIF-1α is a molecular determinant of prolyl hydroxylation. FASEB J. 03-
1233fje.
125. Esteban, M. A. and Maxwell, P. H. (2005). HIF, a missing link between metabolism and cancer. Nat
Med 11, 1047-1048.
126. Knowles, H. J., Raval, R. R., Harris, A. L., and Ratcliffe, P. J. (2003). Effect of ascorbate on the
activity of hypoxia-inducible factor in cancer cells. Cancer Res 63 , 1764-1768.
127. Clarke, H. and Pallister, C. J. (2005). The impact of anaemia on outcome in cancer. Clin Lab
Haematol 27, 1-13.
128. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2003). Characterization of
the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor. J.Biol.Chem. 278,
30772-30780.
129. Erez, N., Stambolsky, P., Shats, I., Milyavsky, M., Kachko, T., and Rotter, V. (2004). Hypoxia-
dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene
promoter. FEBS Letters 567, 311-315.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
135
130. Marxsen, J. H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., Jelkmann, W.,
Jaakkola, P., and Metzen, E. (2004). Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by
induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 381, 761-767.
131. Aprelikova, O., Chandramouli, G. V., Wood, M., Vasselli, J. R., Riss, J., Maranchie, J. K., Linehan,
W. M., and Barrett, J. C. (2004). Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
J Cell Biochem 92, 491-501.
132. Berra, E., Richard, D. E., Gothie, E., and Pouyssegur, J. (2001). HIF-1-dependent transcriptional
activity is required for oxygen-mediated HIF-1[alpha] degradation. FEBS Letters 491, 85-90.
133. Nakayama, K., Frew, I. J., Hagensen, M., Skals, M., Habelhah, H., Bhoumik, A., Kadoya, T.,
Erdjument-Bromage, H., Tempst, P., Frappell, P. B., Bowtell, D. D., and Ronai, Z. (2004). Siah2
regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates
physiological responses to hypoxia. Cell 117, 941-952.
134. Appelhoff, R. J., Tian, Y. M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and
Gleadle, J. M. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the
regulation of hypoxia-inducible factor. J Biol Chem. 279, 38458-38465.
135. Tuckerman, J. R., Zhao, Y., Hewitson, K. S., Tian, Y. M., Pugh, C. W., Ratcliffe, P. J., and Mole, D.
R. (2004). Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS
Letters 576, 145-150.
136. Chan, D. A., Sutphin, P. D., Yen, S. E., and Giaccia, A. J. (2005). Coordinate regulation of the
oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25, 6415-
6426.
137. Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang,
W. Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H., and Fandrey, J. (2003).
Intracellular localisation of human HIF-1{alpha} hydroxylases: implications for oxygen sensing. J
Cell Sci 116, 1319.
138. Baek, J. H., Mahon, P. C., Oh, J., Kelly, B., Krishnamachary, B., Pearson, M., Chan, D. A., Giaccia,
A. J., and Semenza, G. L. (2005). OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl
hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17, 503-512.
139. Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D., and Pouyssegur, J. (2003). HIF prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1{alpha} in normoxia.
EMBO J. 22, 4082-4090.
140. Madden, S. L., Galella, E. A., Riley, D., Bertelsen, A. H., and Beaudry, G. A. (1996). Induction of cell
growth regulatory genes by p53. Cancer Res 56, 5384-5390.
141. Seth, P., Krop, I., Porter, D., and Polyak, K. (2002). Novel estrogen and tamoxifen induced genes
identified by SAGE (Serial Analysis of Gene Expression). Oncogene 21, 836-843.
142. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo, M. A., Song, E. J.,
Lee, K. J., and Kim, K. W. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated
acetylation. Cell 111, 709-720.
143. Bilton, R., Mazure, N., Trottier, E., Hattab, M., Dery, M. A., Richard, D. E., Pouyssegur, J., and
Brahimi-Horn, M. C. (2005). Arrest-defective-1 protein, an acetyltransferase, does not alter stability
of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem. 280,
31132-31140.
144. Arnesen, T., Kong, X., Evjenth, R., Gromyko, D., Varhaug, J. E., Lin, Z., Sang, N., Caro, J., and
Lillehaug, J. R. (2005). Interaction between HIF-1alpha (ODD) and hARD1 does not induce
acetylation and destabilization of HIF-1alpha. FEBS Lett. 579, 6428-6432.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
136
145. Fisher, T. S., Etages, S. D., Hayes, L., Crimin, K., and Li, B. (2005). Analysis of ARD1 function in
hypoxia response using retroviral RNA interference. J Biol Chem. 280, 17749-17757.
146. Li, L. and Deng, X. W. (2003). The COP9 signalosome: an alternative lid for the 26S proteasome?
Trends Cell Biol 13, 507-509.
147. Bemis, L., Chan, D. A., Finkielstein, C. V., Qi, L., Sutphin, P. D., Chen, X., Stenmark, K., Giaccia, A.
J., and Zundel, W. (2004). Distinct aerobic and hypoxic mechanisms of HIF-{alpha} regulation by
CSN5. Genes Dev. 18, 739-744.
148. Li, Z., Wang, D., Messing, E. M., and Wu, G. (2005). VHL protein-interacting deubiquitinating
enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 6, 373-378.
149. Mekhail, K., Gunaratnam, L., Bonicalzi, M. E., and Lee, S. (2004). HIF activation by pH-dependent
nucleolar sequestration of VHL. Nat Cell Biol 6, 642-647.
150. Karhausen, J., Kong, T., Narravula, S., and Colgan, S. P. (2005). Induction of the von Hippel-Lindau
tumor suppressor gene by late hypoxia limits HIF-1 expression. J Cell Biochem 95, 1264-1275.
151. Bae, S. H., Jeong, J. W., Park, J. A., Kim, S. H., Bae, M. K., Choi, S. J., and Kim, K. W. (2004).
Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys.Res
Commun. 324, 394-400.
152. Seeler, J. S. and Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol
4, 690-699.
153. Shao, R., Zhang, F. P., Tian, F., Anders, F. P., Wang, X., Sjoland, H., and Billig, H. (2004). Increase
of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse
brain and heart in vivo. FEBS Lett. 569, 293-300.
154. Tojo, M., Matsuzaki, K., Minami, T., Honda, Y., Yasuda, H., Chiba, T., Saya, H., Fujii-Kuriyama, Y.,
and Nakao, M. (2002). The aryl hydrocarbon receptor nuclear transporter is modulated by the
SUMO-1 conjugation system. J Biol Chem. 277, 46576-46585.
155. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y.,
Lowe, S. W., Kastan, M., and Giaccia, A. (2001). Regulation of p53 by hypoxia: dissociation of
transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21,
1297-1310.
156. Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., and Simon, M. C. (2004). p53 cannot be
induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23, 4975-4983.
157. Kaluzova, M., Kaluz, S., Lerman, M. I., and Stanbridge, E. J. (2004). DNA damage is a prerequisite
for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the
hypoxia marker carbonic anhydrase IX. Mol Cell Biol 24, 5757-5766.
158. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E.,
Madan, A., Semenza, G. L., and Bedi, A. (2000). Regulation of tumor angiogenesis by p53-induced
degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44.
159. Suzuki, H., Tomida, A., and Tsuruo, T. (2001). Dephosphorylated hypoxia-inducible factor 1alpha
as a mediator of p53- dependent apoptosis during hypoxia. Oncogene 20, 5779-5788.
160. Bae, M. K., Ahn, M. Y., Jeong, J. W., Bae, M. H., Lee, Y. M., Bae, S. K., Park, J. W., Kim, K. R., and
Kim, K. W. (2001). Jab1 Interacts Directly with HIF-1alpha and Regulates Its Stability. J.Biol.Chem.
277, 9-12.
161. Hansson, L. O., Friedler, A., Freund, S., Rudiger, S., and Fersht, A. R. (2002). Two sequence motifs
from HIF-1alpha bind to the DNA-binding site of p53. PNAS 99, 10305-10309.
162. Chen, D., Li, M., Luo, J., and Gu, W. (2003). Direct Interactions between HIF-1alpha and Mdm2
Modulate p53 Function. J.Biol.Chem. 278, 13595.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
137
163. Schmid, T., Zhou, J., Kohl, R., and Brune, B. (2004). p300 relieves p53-evoked transcriptional
repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 380, 289-295.
164. Nieminen, A. L., Qanungo, S., Schneider, E. A., Jiang, B. H., and Agani, F. H. (2005). Mdm2 and
HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 204 , 364-369.
165. Zhang, L. and Hill, R. P. (2004). Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in
KHT cells and increasing resistance to apoptosis. Cancer Res 64, 4180-4189.
166. Yoo, Y. G., Yeo, M. G., Kim, D. K., Park, H., and Lee, M. O. (2004). Novel Function of Orphan
Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1{alpha}. J.Biol.Chem. 279, 53365-
53373.
167. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. (1998).
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408.
168. Wenger, R. H., Camenisch, G., Desbaillets, I., Chilov, D., and Gassmann, M. (1998). Up-regulation
of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 58,
5678-5680.
169. Jiang, B. H., Semenza, G. L., Bauer, C., and Marti, H. H. (1996). Hypoxia-inducible factor 1 levels
vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271, C1172-
C1180.
170. Schmid, T., Zhou, J., and Brune, B. (2004). HIF-1 and p53: communication of transcription factors
under hypoxia. J Cell Mol Med 8, 423-431.
171. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J., and Michiels, C. (1999).
Hypoxia-induced activation of HIF-1: role of HIF-1[alpha]-Hsp90 interaction. FEBS Letters 460, 251-
256.
172. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002).
Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative
Pathway. J.Biol.Chem. 277, 29936-29944.
173. Hur, E., Kim, H. H., Choi, S. M., Kim, J. H., Yim, S., Kwon, H. J., Choi, Y., Kim, D. K., Lee, M. O.,
and Park, H. (2002). Reduction of hypoxia-induced transcription through the repression of hypoxia-
inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa
heat-shock protein inhibitor radicicol. Mol Pharmacol 62, 975-982.
174. Agani, F. H., Puchowicz, M., Chavez, J. C., Pichiule, P., and LaManna, J. (2002). Role of nitric
oxide in the regulation of HIF-1alpha expression during hypoxia. Am.J.Physiol Cell Physiol 283,
C178-C186.
175. Hagen, T., Taylor, C. T., Lam, F., and Moncada, S. (2003). Redistribution of Intracellular Oxygen in
Hypoxia by Nitric Oxide: Effect on HIF1{alpha}. Science 302, 1975-1978.
176. Palmer, L. A., Semenza, G. L., Stoler, M. H., and Johns, R. A. (1998). Hypoxia induces type II NOS
gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 274, L212-L219.
177. Mateo, J., Garcia-Lecea, M., Cadenas, S., Hernandez, C., and Moncada, S. (2003). Regulation of
hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent
pathways. Biochem J 376, 537-544.
178. Denko, N., Wernke-Dollries, K., Johnson, A. B., Hammond, E., Chiang, C. M., and Barton, M. C.
(2003). Hypoxia Actively Represses Transcription by Inducing Negative Cofactor 2 (Dr1/DrAP1) and
Blocking Preinitiation Complex Assembly. J.Biol.Chem. 278 , 5744.
179. Wouters, B. G., van den, B. T., Magagnin, M. G., Koritzinsky, M., Fels, D., and Koumenis, C.
(2005). Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev
Biol 16, 487-501.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
138
180. Lang, K. J. D., Kappel, A., and Goodall, G. J. (2002). Hypoxia-inducible Factor-1alpha mRNA
Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and
Hypoxia. Mol.Biol.Cell 13, 1792.
181. Rossignol, F., Vache, C., and Clottes, E. (2002). Natural antisense transcripts of hypoxia-inducible
factor 1alpha are detected in different normal and tumour human tissues. Gene 299, 135-140.
182. Arany, Z., Huang, L. á., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M., Bunn, H. á., and
Livingston, D. (1996). An essential role for p300/CBP in the cellular response to hypoxia. PNAS 93,
12969-12973.
183. Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., and Poellinger, L. (2000).
Redox-regulated recruitment of the transcriptional coactivators CREB- binding protein and SRC-1 to
hypoxia-inducible factor 1alpha. Mol Cell Biol. 20, 402-415.
184. Lando, D., Pongratz, I., Poellinger, L., and Whitelaw, M. L. (2000). A Redox Mechanism Controls
Differential DNA Binding Activities of Hypoxia-inducible Factor (HIF) 1alpha and the HIF-like Factor.
J.Biol.Chem. 275, 4618-4627.
185. McNeill, L. A., Hewitson, K. S., Claridge, T. D., Seibel, J. F., Horsfall, L. E., and Schofield, C. J.
(2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the
beta-carbon of asparagine-803. Biochem J 367, 571-575.
186. Freedman, S. J., Sun, Z. Y., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., and Eck, M. J.
(2002). Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha. PNAS 99,
5367-5372.
187. Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L., and Peet, D. J. (2004).
Substrate Requirements of the Oxygen-sensing Asparaginyl Hydroxylase Factor-inhibiting Hypoxia-
inducible Factor. J.Biol.Chem. 279, 14391-14397.
188. Lancaster, D. E., McNeill, L. A., McDonough, M. A., Aplin, R. T., Hewitson, K. S., Pugh, C. W.,
Ratcliffe, P. J., and Schofield, C. J. (2004). Disruption of dimerization and substrate phosphorylation
inhibit factor inhibiting hypoxia-inducible factor (FIH) activity. Biochem J 383, 429-437.
189. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002). Asparagine
Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch. Science 295, 858-861.
190. Koivunen, P., Hirsila, M., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2004). Catalytic Properties
of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of Its
Prolyl 4-Hydroxylases. J.Biol.Chem. 279, 9899-9904.
191. Koshiji, M., Kageyama, Y., Pete, E. A., Horikawa, I., Barrett, J. C., and Huang, L. E. (2004). HIF-
1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23, 1949-1956.
192. Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., and Ryu, S. E. (2003). Structure of Human FIH-1
Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau.
J.Biol.Chem. 278, 7558.
193. Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., and Caro, J. (2002). Carboxyl-terminal
transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau
protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22, 2984-
2992.
194. Mahon, P. C., Hirota, K., and Semenza, G. L. (2001). FIH-1: a novel protein that interacts with HIF-
1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686.
195. Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., and Wu, G. (2003). The VHL protein
recruits a novel KRAB-A domain protein to repress HIF-1{alpha} transcriptional activity. EMBO J.
22, 1857.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
139
196. Kato, H., Tamamizu-Kato, S., and Shibasaki, F. (2004). Histone deacetylase 7 associates with
hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem. 279, 41966-
41974.
197. Minet, E., Michel, G., Mottet, D., Raes, M., and Michiels, C. (2001). Transduction pathways involved
in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic.Biol.Med. 31, 847-855.
198. Sodhi, A., Montaner, S., Miyazaki, H., and Gutkind, J. S. (2001). MAPK and Akt act cooperatively
but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF.
Biochem.Biophys.Res Commun. 287, 292-300.
199. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. (2001). Phosphatidylinositol
3-kinase signaling controls levels of hypoxia- inducible factor 1. Cell Growth Differ. 12, 363-369.
200. Alvarez-Tejado, M., Alfranca, A., Aragones, J., Vara, A., Landazuri, M. O., and del Peso, L. (2002).
Lack of Evidence for the Involvement of the Phosphoinositide 3-Kinase/Akt Pathway in the
Activation of Hypoxia-inducible Factors by Low Oxygen Tension. J.Biol.Chem. 277, 13508-13517.
201. Arsham, A. M., Howell, J. J., and Simon, M. C. (2003). A Novel Hypoxia-inducible Factor-
independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets.
J.Biol.Chem. 278, 29655-29660.
202. Tang, T. T.-L. and Lasky, L. A. (2003). The Forkhead Transcription Factor FOXO4 Induces the
Down-regulation of Hypoxia-inducible Factor 1{alpha} by a von Hippel-Lindau Protein-independent
Mechanism. J.Biol.Chem. 278, 30125-30135.
203. Zhou, J., Schmid, T., Frank, R., and Brune, B. (2004). PI3K/Akt Is Required for Heat Shock Proteins
to Protect Hypoxia-inducible Factor 1{alpha} from pVHL-independent Degradation. J.Biol.Chem.
279, 13506-13513.
204. Beitner-Johnson, D., Rust, R. T., Hsieh, T. C., and Millhorn, D. E. (2001). Hypoxia activates Akt and
induces phosphorylation of GSK-3 in PC12 cells. Cell Signal. 13, 23-27.
205. Mottet, D., Dumont, V., Deccache, Y., Demazy, C., Ninane, N., Raes, M., and Michiels, C. (2003).
Regulation of Hypoxia-inducible Factor-1{alpha} Protein Level during Hypoxic Conditions by the
Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3{beta} Pathway in HepG2 Cells.
J.Biol.Chem. 278, 31277-31285.
206. Hur, E., Chang, K. Y., Lee, E., Lee, S. K., and Park, H. (2001). Mitogen-activated protein kinase
kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability
of hypoxia-inducible factor-1alpha. Mol Pharmacol 59, 1216-1224.
207. Berra, E., Milanini, J., Richard, D. E., Le Gall, M., Vinals, F., Gothie, E., Roux, D., Pages, G., and
Pouyssegur, J. (2000). Signaling angiogenesis via p42/p44 MAP kinase and hypoxia.
Biochem.Pharmacol 60, 1171-1178.
208. Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., and Caro, J. (2003). MAPK
Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300. J.Biol.Chem.
278, 14013.
209. Liu, C., Shi, Y., Han, Z., Pan, Y., Liu, N., Han, S., Chen, Y., Lan, M., Qiao, T., and Fan, D. (2003).
Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and
increases expression of EPO. Biochemical and Biophysical Research Communications 312, 780-
786.
210. Conrad, P. W., Rust, R. T., Han, J., Millhorn, D. E., and Beitner-Johnson, D. (1999). Selective
activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in
PC12 cells. J Biol Chem. 274, 23570-23576.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
140
211. Le, Y. J. and Corry, P. M. (1999). Hypoxia-induced bFGF gene expression is mediated through the
JNK signal transduction pathway. Mol Cell Biochem 202, 1-8.
212. Lee, M., Hwang, J. T., Lee, H. J., Jung, S. N., Kang, I., Chi, S. G., Kim, S. S., and Ha, J. (2003).
AMP-activated Protein Kinase Activity Is Critical for Hypoxia-inducible Factor-1 Transcriptional
Activity and Its Target Gene Expression under Hypoxic Conditions in DU145 Cells. J.Biol.Chem.
278, 39653-39661.
213. Mottet, D., Ruys, S. P., Demazy, C., Raes, M., and Michiels, C. (2005). Role for casein kinase 2 in
the regulation of HIF-1 activity. Int J Cancer 117, 764-774.
214. Colavitti, R., Pani, G., Bedogni, B., Anzevino, R., Borrello, S., Waltenberger, J., and Galeotti, T.
(2002). Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular
Endothelial Growth Factor Receptor-2/KDR. J.Biol.Chem. 277, 3101-3108.
215. Zulueta, J. J., Yu, F. S., Hertig, I. A., Thannickal, V. J., and Hassoun, P. M. (1995). Release of
hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme
in endothelial cell plasma membrane. Am J Respir.Cell Mol Biol 12, 41-49.
216. Osada, M., Imaoka, S., Sugimoto, T., Hiroi, T., and Funae, Y. (2002). NADPH-Cytochrome P-450
Reductase in the Plasma Membrane Modulates the Activation of Hypoxia-inducible Factor 1.
J.Biol.Chem. 277, 23367-23373.
217. Bell, E. L., Emerling, B. M., and Chandel, N. S. (2005). Mitochondrial regulation of oxygen sensing.
Mitochondrion. 5, 322-332.
218. Mansfield, K. D., Guzy, R. D., Pan, Y., Young, R. M., Cash, T. P., Schumacker, P. T., and Simon,
M. C. (2005). Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen
sensing and hypoxic HIF-alpha activation. Cell Metab 1, 393-399.
219. Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M.,
and Schumacker, P. T. (2000). Reactive Oxygen Species Generated at Mitochondrial Complex III
Stabilize Hypoxia-inducible Factor-1alpha during Hypoxia. A MECHANISM OF O2 SENSING.
J.Biol.Chem. 275, 25130-25138.
220. Sanjuan-Pla, A., Cervera, A. M., Apostolova, N., Garcia-Bou, R., Victor, V. M., Murphy, M. P., and
McCreath, K. J. (2005). A targeted antioxidant reveals the importance of mitochondrial reactive
oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett. 579, 2669-2674.
221. Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., and Schumacker, P. T.
(1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad
Sci U S A 95, 11715-11720.
222. Vaux, E. C., Metzen, E., Yeates, K. M., and Ratcliffe, P. J. (2001). Regulation of hypoxia-inducible
factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98, 296-
302.
223. Emerling, B. M., Platanias, L. C., Black, E., Nebreda, A. R., Davis, R. J., and Chandel, N. S. (2005).
Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required
for hypoxia signaling. Mol Cell Biol 25, 4853-4862.
224. Schroedl, C., McClintock, D. S., Budinger, G. R., and Chandel, N. S. (2002). Hypoxic but not anoxic
stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am.J Physiol Lung Cell
Mol Physiol 283, L922-L931.
225. To, K. K. and Huang, L. E. (2005). Suppression of HIF-1alpha transcriptional activity by the HIF
prolyl hydroxylase EGLN1. J Biol Chem.
226. Ozer, A., Wu, L. C., and Bruick, R. K. (2005). The candidate tumor suppressor ING4 represses
activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A 102, 7481-7486.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
141
227. Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A., and Ohh, M. (2005). Human HIF-
3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma.
FASEB J 19, 1396-1406.
228. Bhattacharya, S., Michels, C. L., Leung, M. K., Arany, Z. P., Kung, A. L., and Livingston, D. M.
(1999). Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1.
Genes Dev. 13, 64-75.
229. Fox, S. B., Braganca, J., Turley, H., Campo, L., Han, C., Gatter, K. C., Bhattacharya, S., and Harris,
A. L. (2004). CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic
location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible
factor 1alpha. Cancer Res 64, 6075-6081.
230. Tacchini, L., Dansi, P., Matteucci, E., and Desiderio, M. A. (2001). Hepatocyte growth factor
signalling stimulates hypoxia inducible factor- 1 (HIF-1) activity in HepG2 hepatoma cells.
Carcinogenesis 22, 1363-1371.
231. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. (2002). Insulin-like
growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor
expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon
cancer cells. J Biol.Chem. 277, 38205-38211.
232. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W.,
and Semenza, G. L. (2000). Modulation of Hypoxia-inducible Factor 1{{alpha}} Expression by the
Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human
Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics. Cancer Res 60,
1541-1545.
233. Shi, Y. H., Wang, Y. X., You, J. F., Heng, W. J., Zhong, H. H., and Fang, W. G. (2004). [Activation
of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways.]. Zhonghua Yi.Xue.Za
Zhi. 84, 1899-1903.
234. Stiehl, D. P., Jelkmann, W., Wenger, R. H., and Hellwig-Burgel, T. (2002). Normoxic induction of the
hypoxia-inducible factor 1[alpha] by insulin and interleukin-1[beta] involves the phosphatidylinositol
3-kinase pathway. FEBS Letters 512, 157-162.
235. Moeller, L. C., Dumitrescu, A. M., and Refetoff, S. (2005). Cytosolic action of thyroid hormone leads
to induction of hypoxia-inducible factor-1alpha and glycolytic genes. Mol Endocrinol 19, 2955-2963.
236. Mabjeesh, N. J., Willard, M. T., Frederickson, C. E., Zhong, H., and Simons, J. W. (2003).
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase
receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9,
2416-2425.
237. Zhou, J., Schmid, T., and Brune, B. (2003). Tumor Necrosis Factor-{alpha} Causes Accumulation of
a Ubiquitinated Form of Hypoxia Inducible Factor-1{alpha} through a Nuclear Factor-{kappa}B-
Dependent Pathway. Mol.Biol.Cell 14, 2216-2225.
238. Spinella, F., Rosano, L., Di Castro, V., Natali, P. G., and Bagnato, A. (2002). Endothelin-1 Induces
Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1alpha in Ovarian
Carcinoma Cells. J.Biol.Chem. 277, 27850-27855.
239. Chun, Y. S., Choi, E., Kim, G. T., Lee, M. J., Lee, M. J., Lee, S. E., Kim, M. S., and Park, J. W.
(2000). Zinc induces the accumulation of hypoxia-inducible factor (HIF)-1alpha, but inhibits the
nuclear translocation of HIF-1beta, causing HIF-1 inactivation. Biochem.Biophys.Res Commun.
268, 652-656.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
142
240. Lee, S. G., Lee, H., and Rho, H. M. (2001). Transcriptional repression of the human p53 gene by
cobalt chloride mimicking hypoxia. FEBS Lett. 507, 259-263.
241. Gao, N., Ding, M., Zheng, J. Z., Zhang, Z., Leonard, S. S., Liu, K. J., Shi, X., and Jiang, B. H.
(2002). Vanadate-induced Expression of Hypoxia-inducible Factor 1alpha and Vascular Endothelial
Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species.
J.Biol.Chem. 277, 31963-31971.
242. Gao, N., Jiang, B. H., Leonard, S. S., Corum, L., Zhang, Z., Roberts, J. R., Antonini, J., Zheng, J. Z.,
Flynn, D. C., Castranova, V., and Shi, X. (2002). p38 Signaling-mediated hypoxia-inducible factor
1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate
carcinoma cells. J.Biol.Chem. 277, 45041-45048.
243. Sandau, K. B., Zhou, J., Kietzmann, T., and Brune, B. (2001). Regulation of the Hypoxia-inducible
Factor 1alpha by the Inflammatory Mediators Nitric Oxide and Tumor Necrosis Factor-alpha in
Contrast to Desferroxamine and Phenylarsine Oxide. J.Biol.Chem. 276, 39805-39811.
244. Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H. M., and Harris, A. L. (2002). A mycobacterial
iron chelator, desferri-exochelin, induces hypoxia- inducible factors 1 and 2, NIP3, and vascular
endothelial growth factor in cancer cell lines. Cancer Res 62, 6924-6927.
245. Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. Activation of the HIF pathway in cancer. Current
Opinion in Genetics and Development 11, 293-299. 2001.
Ref Type: Generic
246. Wakisaka, N., Kondo, S., Yoshizaki, T., Murono, S., Furukawa, M., and Pagano, J. S. (2004).
Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
Mol Cell Biol 24, 5223-5234.
247. Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L., and Bernabeu, C. (2001).
Synergistic Cooperation between Hypoxia and Transforming Growth Factor-beta Pathways on
Human Vascular Endothelial Growth Factor Gene Expression. J.Biol.Chem. 276, 38527-38535.
248. Zhang, S. X. L., Gozal, D., Sachleben, J., Rane, M., Klein, J. B., and Gozal, E. (2003). Hypoxia
induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-
β receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J. 02-
1111fje.
249. Tacchini, L., Matteucci, E., De Ponti, C., and Desiderio, M. A. (2003). Hepatocyte growth factor
signaling regulates transactivation of genes belonging to the plasminogen activation system via
hypoxia inducible factor-1. Exp Cell Res 290, 391-401.
250. Zhu, G., Saed, G. M., Deppe, G., Diamond, M. P., and Munkarah, A. R. (2004). Hypoxia up-
regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
Gynecol.Oncol 94, 422-426.
251. Lison, D., De Boeck, M., Verougstraete, V., and Kirsch-Volders, M. (2001). Update on the
genotoxicity and carcinogenicity of cobalt compounds. Occup.Environ.Med 58, 619-625.
252. Williams, D. R. (1972). Metals, ligands, and cancer. Chem.Rev 72, 203-213.
253. Salnikow, K., Donald, S. P., Bruick, R. K., Zhitkovich, A., Phang, J. M., and Kasprzak, K. S. (2004).
Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the
induction of hypoxic stress. J Biol Chem. 279, 40337-40344.
254. Hirsila, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K. I., and Myllyharju, J. (2005). Effect of
desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19,
1308-1310.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
143
255. Yuan, Y., Beitner-Johnson, D., and Millhorn, D. E. (2001). Hypoxia-inducible factor 2alpha binds to
cobalt in vitro. Biochem.Biophys.Res Commun. 288, 849-854.
256. Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D. E. (2003). Cobalt Inhibits the Interaction
between Hypoxia-inducible Factor-alpha and von Hippel-Lindau Protein by Direct Binding to
Hypoxia-inducible Factor-alpha. J.Biol.Chem. 278, 15911.
257. Kanaya, K., Tsai, A. L., and Kamitani, T. (2002). Cobalt- and nickel-binding property of cullin-2.
Biochem.Biophys.Res Commun. 290, 294-299.
258. Chachami, G., Simos, G., Hatziefthimiou, A., Bonanou, S., Molyvdas, P. A., and Paraskeva, E.
(2004). Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by
a reactive oxygen species- and PI3K-dependent mechanism. Am J Respir.Cell Mol Biol 31, 544-
551.
259. Peters, K., Schmidt, H., Unger, R. E., Kamp, G., Prols, F., Berger, B. J., and Kirkpatrick, C. J.
(2005). Paradoxical effects of hypoxia-mimicking divalent cobalt ions in human endothelial cells in
vitro. Mol Cell Biochem 270, 157-166.
260. Sandau, K. B., Fandrey, J., and Brune, B. (2001). Accumulation of HIF-1alpha under the influence
of nitric oxide. Blood 97, 1009-1015.
261. Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L.,
and Hirota, K. (2004). Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent
on MAPK and Phosphatidylinositol 3-Kinase Signaling. J.Biol.Chem. 279, 2550-2558.
262. Yasinska, I. M. and Sumbayev, V. V. (2003). S-nitrosation of Cys-800 of HIF-1[alpha] protein
activates its interaction with p300 and stimulates its transcriptional activity. FEBS Letters 549, 105-
109.
263. Zhang, Z., Ren, J., Harlos, K., McKinnon, C. H., Clifton, I. J., and Schofield, C. J. (2002). Crystal
structure of a clavaminate synthase-Fe(II)-2-oxoglutarate-substrate-NO complex: evidence for metal
centered rearrangements. FEBS Lett. 517, 7-12.
264. Zhong, H., Mabjeesh, N., Willard, M., and Simons, J. (2002). Nuclear expression of hypoxia-
inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic
conditions. Cancer Lett. 181, 233-238.
265. Anastasiadis, A. G., Ghafar, M. A., Salomon, L., Vacherot, F., Benedit, P., Chen, M. W., Shabsigh,
A., Burchardt, M., Chopin, D. K., Shabsigh, R., and Buttyan, R. (2002). Human hormone-refractory
prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia
inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol 128, 358-362.
266. Chau, C. H., Permenter, M. G., Steinberg, S. M., Retter, A. S., Dahut, W. L., Price, D. K., and Figg,
W. D. (2005). Polymorphism in the Hypoxia-Inducible Factor 1alpha Gene May Confer Susceptibility
to Androgen-Independent Prostate Cancer. Cancer Biol Ther 4.
267. Tanimoto, K., Yoshiga, K., Eguchi, H., Kaneyasu, M., Ukon, K., Kumazaki, T., Oue, N., Yasui, W.,
Imai, K., Nakachi, K., Poellinger, L., and Nishiyama, M. (2003). Hypoxia-inducible factor-1alpha
polymorphisms associated with enhanced transactivation capacity, implying clinical significance.
Carcinogenesis 24, 1779-1783.
268. Ollerenshaw, M., Page, T., Hammonds, J., and Demaine, A. (2004). Polymorphisms in the hypoxia
inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype.
Cancer Genet Cytogenet. 153, 122-126.
269. Kuwai, T., Kitadai, Y., Tanaka, S., Kuroda, T., Ochiumi, T., Matsumura, S., Oue, N., Yasui, W.,
Kaneyasu, M., Tanimoto, K., Nishiyama, M., and Chayama, K. (2004). Single nucleotide
Mecanismes de resposta a la inducció per hipòxia Bibliografia
144
polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep. 12,
1033-1037.
270. Fu, X. S., Choi, E., Bubley, G. J., and Balk, S. P. (2005). Identification of hypoxia-inducible factor-
1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced
degradation. Prostate 63, 215-221.
271. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G., Jr. (2002). Inhibition of HIF
is necessary for tumor suppression by the von Hippel- Lindau protein. Cancer Cell 1, 237-246.
272. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and Klausner, R. D.
(2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in
renal cell carcinoma. Cancer Cell 1, 247-255.
273. Miller, F., Kentsis, A., Osman, R., and Pan, Z. Q. (2005). Inactivation of VHL by Tumorigenic
Mutations That Disrupt Dynamic Coupling of the pVHL{middle dot}Hypoxia-inducible Transcription
Factor-1{alpha} Complex. J.Biol.Chem. 280, 7985-7996.
274. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L.,
McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.
H., and Parsons, R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science 275, 1943-1947.
275. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan,
H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. (2000). Loss of PTEN
facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396.
276. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human
cancers. Science 253, 49-53.
277. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2.
Nature 387, 299-303.
278. Fatyol, K. and Szalay, A. A. (2001). The p14ARF Tumor Suppressor Protein Facilitates Nucleolar
Sequestration of Hypoxia-inducible Factor-1alpha (HIF-1alpha ) and Inhibits HIF-1-mediated
Transcription. J.Biol.Chem. 276, 28421-28429.
279. Chan, D. A., Sutphin, P. D., Denko, N. C., and Giaccia, A. J. (2002). Role of prolyl hydroxylation in
oncogenically stabilized hypoxia- inducible factor-1alpha. J.Biol.Chem. 277, 40112-40117.
280. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. (1997). Induction of vascular
endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling
pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.
Blood 90, 3322-3331.
281. Racker, E., Resnick, R. J., and Feldman, R. (1985). Glycolysis and methylaminoisobutyrate uptake
in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci U S A 82, 3535-3538.
282. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. (1995).
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of
tumor angiogenesis. Cancer Res 55, 4575-4580.
283. Blancher, C., Moore, J. W., Robertson, N., and Harris, A. L. (2001). Effects of ras and von Hippel-
Lindau (VHL) Gene Mutations on Hypoxia-inducible Factor (HIF)-1{alpha}, HIF-2{alpha}, and
Vascular Endothelial Growth Factor Expression and Their Regulation by the Phosphatidylinositol 3'-
Kinase/Akt Signaling Pathway. Cancer Res 61, 7349-7355.
284. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J.,
Waterfield, M. D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a direct target of
Ras. Nature 370, 527-532.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
145
285. Pouyssegur, J., Volmat, V., and Lenormand, P. (2002). Fidelity and spatio-temporal control in MAP
kinase (ERKs) signalling. Biochem Pharmacol 64, 755-763.
286. Karni, R., Dor, Y., Keshet, E., Meyuhas, O., and Levitzki, A. (2002). Activated pp60c-Src leads to
elevated hypoxia-inducible factor (HIF)- 1alpha expression under normoxia. J Biol.Chem. 277,
42919-42925.
287. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M.,
Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D.,
Keshert, E., and Keshet, E. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell
proliferation and tumour angiogenesis. Nature 394, 485-490.
288. Uchida, T., Rossignol, F., Matthay, M. A., Mounier, R., Couette, S., Clottes, E., and Clerici, C.
(2004). Prolonged Hypoxia Differentially Regulates Hypoxia-inducible Factor (HIF)-1{alpha} and
HIF-2{alpha} Expression in Lung Epithelial Cells: IMPLICATION OF NATURAL ANTISENSE HIF-
1{alpha}. J.Biol.Chem. 279, 14871-14878.
289. Demidenko, Z. N., Rapisarda, A., Garayoa, M., Giannakakou, P., Melillo, G., and Blagosklonny, M.
V. (2005). Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent
depletion. Oncogene 24, 4829-4838.
290. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., and Simon, M. C. (2003). Differential roles of
hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell
Biol 23, 9361-9374.
291. Bracken, C. P., Whitelaw, M. L., and Peet, D. J. (2005). Activity of Hypoxia-inducible Factor 2{alpha}
Is Regulated by Association with the NF-{kappa}B Essential Modulator. J.Biol.Chem. 280, 14240-
14251.
292. Wiesener, M. S., Jurgensen, J. S., Rosenberger, C., Scholze, C. K., Horstrup, J. H., Warnecke, C.,
Mandriota, S., Bechmann, I., Frei, U. A., Pugh, C. W., Ratcliffe, P. J., Bachmann, S., Maxwell, P. H.,
and Eckardt, K. U. (2003). Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell
populations of different organs. FASEB J 17, 271-273.
293. Wiesener, M. S., Turley, H., Allen, W. E., Willam, C., Eckardt, K. U., Talks, K. L., Wood, S. M.,
Gatter, K. C., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and Maxwell, P. H. (1998). Induction of
endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-
inducible factor-1alpha. Blood 92, 2260-2268.
294. Holmquist, L., Jogi, A., and Pahlman, S. (2005). Phenotypic persistence after reoxygenation of
hypoxic neuroblastoma cells. Int J Cancer 116, 218-225.
295. Wang, V., Davis, D. A., Haque, M., Huang, L. E., and Yarchoan, R. (2005). Differential Gene Up-
Regulation by Hypoxia-Inducible Factor-1{alpha} and Hypoxia-Inducible Factor-2{alpha} in
HEK293T Cells. Cancer Res 65, 3299-3306.
296. Brusselmans, K., Bono, F., Maxwell, P., Dor, Y., Dewerchin, M., Collen, D., Herbert, J. M., and
Carmeliet, P. (2001). Hypoxia-inducible Factor-2alpha (HIF-2alpha ) Is Involved in the Apoptotic
Response to Hypoglycemia but Not to Hypoxia. J.Biol.Chem. 276, 39192-39196.
297. Bertges, D. J., Berg, S., Fink, M. P., and Delude, R. L. (2002). Regulation of hypoxia-inducible
factor 1 in enterocytic cells. J.Surg.Res 106, 157-165.
298. Belanger, A. J., Lu, H., Date, T., Liu, L. X., Vincent, K. A., Akita, G. Y., Cheng, S. H., Gregory, R. J.,
and Jiang, C. (2002). Hypoxia up-regulates expression of peroxisome proliferator-activated receptor
gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor
1alpha. J.Mol Cell Cardiol. 34 , 765-774.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
146
299. Jung, F., Haendeler, J., Hoffmann, J., Reissner, A., Dernbach, E., Zeiher, A. M., and Dimmeler, S.
(2002). Hypoxic Induction of the Hypoxia-Inducible Factor Is Mediated via the Adaptor Protein Shc
in Endothelial Cells. Circ Res 91, 38.
300. BelAiba, R. S., Djordjevic, T., Bonello, S., Flugel, D., Hess, J., Kietzmann, T., and Gorlach, A.
(2004). Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary
artery smooth muscle cells. Biol Chem. 385, 249-257.
301. Wang, Y. Q., Luk, J. M., Ikeda, K., Man, K., Chu, A. C., Kaneda, K., and Tat Fan, S. (2004).
Regulatory role of vHL/HIF-1[alpha] in hypoxia-induced VEGF production in hepatic stellate cells.
Biochemical and Biophysical Research Communications 317, 358-362.
302. Karhausen, J., Haase, V. H., and Colgan, S. P. (2005). Inflammatory hypoxia: role of hypoxia-
inducible factor. Cell Cycle 4, 256-258.
303. Scortegagna, M., Morris, M. A., Oktay, Y., Bennett, M., and Garcia, J. A. (2003). The HIF family
member EPAS1/HIF-2{alpha} is required for normal hematopoiesis in mice. Blood 102, 1634-1640.
304. Licht, A. H., Muller-Holtkamp, F., Flamme, I., and Breier, G. (2005). Inhibition of hypoxia-inducible
factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood.
305. Freeburg, P. B., Robert, B., St John, P. L., and Abrahamson, D. R. (2003). Podocyte expression of
hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc.Nephrol. 14,
927-938.
306. Wagner, K. F., Hellberg, A. K., Balenger, S., Depping, R., Dodd, O., Johns, R. A., and Li, D. (2004).
Hypoxia-induced mitogenic factor has antiapoptotic action and is upregulated in the developing
lung: coexpression with hypoxia-inducible factor-2alpha. Am J Respir.Cell Mol Biol 31, 276-282.
307. Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M. J., Bennett, M., Shelton, J. M.,
Richardson, J. A., Moe, O., and Garcia, J. A. (2005). HIF-2alpha regulates murine hematopoietic
development in an erythropoietin-dependent manner. Blood 105, 3133-3140.
308. Duan, L. J., Zhang-Benoit, Y., and Fong, G. H. (2005). Endothelium-intrinsic requirement for Hif-
2alpha during vascular development. Circulation 111, 2227-2232.
309. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs,
W. B., Semenza, G. L., and Simons, J. W. (1999). Overexpression of hypoxia-inducible factor
1alpha in common human cancers and their metastases. Cancer Res 59, 5830-5835.
310. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. (2001). Expression of
hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on
response to chemotherapy. Clin.Cancer Res 7, 1661-1668.
311. Theodoropoulos, V. E., Lazaris, A. C., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., Manikas, K.,
and Kastriotis, I. (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis
and unfavorable prognosis in bladder cancer. Eur Urol. 46, 200-208.
312. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch,
J., Pak, B., Taghavi, P., and Semenza, G. L. (2003). Regulation of Colon Carcinoma Cell Invasion
by Hypoxia-Inducible Factor 1. Cancer Res 63, 1138.
313. Jogi, A., Vallon-Christersson, J., Holmquist, L., Axelson, H., Borg, A., and Pahlman, S. (2004).
Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth,
survival, and aggressive behavior. Experimental Cell Research 295, 469-487.
314. Kimura, S., Kitadai, Y., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., and Chayama, K.
(2004). Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial
growth factor expression and tumour angiogenesis in human oesophageal squamous cell
carcinoma. Eur J Cancer 40, 1904-1912.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
147
315. Buchler, P., Reber, H. A., Lavey, R. S., Tomlinson, J., Buchler, M. W., Friess, H., and Hines, O. J.
(2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic
murine model. J Surg.Res 120, 295-303.
316. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., Millard, P., Fuggle, S., and
Harris, A. L. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer:
relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62,
2493-2497.
317. Onita, T., Ji, P. G., Xuan, J. W., Sakai, H., Kanetake, H., Maxwell, P. H., Fong, G. H., Gabril, M. Y.,
Moussa, M., and Chin, J. L. (2002). Hypoxia-induced, perinecrotic expression of endothelial Per-
ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression,
vascularization, and focal macrophage infiltration in bladder cancer. Clin.Cancer Res 8, 471-480.
318. Piret, J. P., Lecocq, C., Toffoli, S., Ninane, N., Raes, M., and Michiels, C. (2004). Hypoxia and
CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible
anti-apoptotic role for HIF-1. Experimental Cell Research 295, 340-349.
319. Weinmann, M., Jendrossek, V., Handrick, R., Guner, D., Goecke, B., and Belka, C. (2004).
Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death
pathway in a FADD/caspase-8 independent manner. Oncogene 23, 3757-3769.
320. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H. P., Johnson, R. S., and Bergers,
G. (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4,
133-146.
321. Teicher, B. A. (1994). Hypoxia and drug resistance. Cancer Metastasis Rev 13, 139-168.
322. Moeller, B. J., Cao, Y., Li, C. Y., and Dewhirst, M. W. (2004). Radiation activates HIF-1 to regulate
vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer
Cell 5, 429-441.
323. Xia, S., Yu, S. Y., Yuan, X. L., and Xu, S. P. (2004). Effects of hypoxia on expression of P-
glycoprotein and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line.
Zhonghua Yi.Xue.Za Zhi. 84, 663-666.
324. Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C.,
Demonacos, C., Stratford, I. J., and Dive, C. (2004). Hypoxia-mediated down-regulation of Bid and
Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and
contributes to drug resistance. Mol Cell Biol 24, 2875-2889.
325. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. (1997). Tumor hypoxia
adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat.Oncol Biol Phys.
38, 285-289.
326. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K.
C., and Harris, A. L. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and
chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int.J.Radiat.Oncol.Biol.Phys.
53, 1192-1202.
327. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., Parker, C. A.,
Stratford, I. J., and Williams, K. J. (2005). REVERSING HYPOXIC CELL CHEMORESISTANCE IN
VITRO USING GENETIC AND SMALL MOLECULE APPROACHES TARGETING HYPOXIA
INDUCIBLE FACTOR-1. Mol Pharmacol.
328. Rak, J. and Yu, J. L. (2004). Oncogenes and tumor angiogenesis: The question of vascular 'supply'
and vascular 'demand'. Seminars in Cancer Biology 14, 93-104.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
148
329. Kaanders, J. H., Pop, L. A., Marres, H. A., Bruaset, I., van den Hoogen, F. J., Merkx, M. A., and van
der Kogel, A. J. (2002). ARCON: experience in 215 patients with advanced head-and-neck cancer.
Int J Radiat.Oncol Biol Phys. 52, 769-778.
330. Brown, J. M. and Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment.
Nat.Rev.Cancer 4, 437-447.
331. Brown, J. M. and Lemmon, M. J. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing
produced by fractionated irradiation of mouse tumors. Cancer Res 50 , 7745-7749.
332. Lunt, S. J., Telfer, B. A., Fitzmaurice, R. J., Stratford, I. J., and Williams, K. J. (2005). Tirapazamine
administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res
11, 4212-4216.
333. Rischin, D., Peters, L., Hicks, R., Hughes, P., Fisher, R., Hart, R., Sexton, M., D'Costa, I., and von
Roemeling, R. (2001). Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in
patients with advanced head and neck cancer. J Clin Oncol 19, 535-542.
334. Dorie, M. J. and Brown, J. M. (1993). Tumor-specific, schedule-dependent interaction between
tirapazamine (SR 4233) and cisplatin. Cancer Res 53, 4633-4636.
335. Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L.,
Penniment, M., Corry, J., Lamb, D., and McClure, B. (2005). Tirapazamine, Cisplatin, and Radiation
versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck
cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
J Clin Oncol 23, 79-87.
336. Patterson, L. H. (2002). Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique
approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34, 581-592.
337. Gallagher, R., Hughes, C. M., Murray, M. M., Friery, O. P., Patterson, L. H., Hirst, D. G., and
McKeown, S. R. (2001). The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
Br J Cancer 85, 625-629.
338. Loadman, P. M., Swaine, D. J., Bibby, M. C., Welham, K. J., and Patterson, L. H. (2001). A
preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab Dispos. 29, 422-426.
339. Wilson, W. R., Tercel, M., Anderson, R. F., and Denny, W. A. (1998). Radiation-activated prodrugs
as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anticancer
Drug Des 13, 663-685.
340. Dai, S., Huang, M. L., Hsu, C. Y., and Chao, K. S. C. (2003). Inhibition of hypoxia inducible factor
1[alpha] causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in
glioblastoma cells. International Journal of Radiation Oncology*Biology*Physics 55, 1027-1036.
341. Sun, X. Y., Meng, F. Q., Jiang, H. C., Qiao, H. Q., and Li, W. (2005). [Antisense hypoxia inducible
factor-1alpha and B7-1 combination gene therapy for mouse lymphoma.]. Zhonghua Zhong.Liu Za
Zhi. 27, 404-407.
342. Mizuno, T., Nagao, M., Yamada, Y., Narikiyo, M., Ueno, M., Miyagishi, M., Taira, K., and Nakajima,
Y. (2005). Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha
inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther .
343. Harada, H., Hiraoka, M., and Kizaka-Kondoh, S. (2002). Antitumor effect of TAT-oxygen-dependent
degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
Cancer Res 62, 2013-2018.
344. Wang, D., Ruan, H., Hu, L., Lamborn, K. R., Kong, E. L., Rehemtulla, A., and Deen, D. F. (2005).
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed
prodrug cancer therapy. Cancer Gene Ther 12, 276-283.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
149
345. Post, D. E. and Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated oncolytic
adenovirus for cancer therapy. Oncogene 22, 2065-2072.
346. Pipiya, T., Sauthoff, H., Huang, Y. Q., Chang, B., Cheng, J., Heitner, S., Chen, S., Rom, W. N., and
Hay, J. G. (2005). Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral
protein expression. Gene Ther 12, 911-917.
347. Shen, B. H. and Hermiston, T. W. (2005). Effect of hypoxia on Ad5 infection, transgene expression
and replication. Gene Ther 12, 902-910.
348. Pin, R. H., Reinblatt, M., Bowers, W. J., Federoff, H. J., and Fong, Y. (2004). Herpes simplex virus
amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in
hepatocellular carcinoma. J Gastrointest.Surg. 8, 812-822.
349. Fox, M. E., Lemmon, M. J., Mauchline, M. L., Davis, T. O., Giaccia, A. J., Minton, N. P., and Brown,
J. M. (1996). Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of
5-fluorocytosine by genetically engineered clostridia. Gene Ther 3, 173-178.
350. Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., and Taniguchi, S. (2001).
Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary
tumors. Breast Cancer Res Treat. 66, 165-170.
351. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., and Melillo, G. (2004).
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic
Implications. Cancer Res 64, 1475-1482.
352. Lund, E. L., Hansen, L. T., and Kristjansen, P. E. (2005). Augmenting tumor sensitivity to topotecan
by transient hypoxia. Cancer Chemother.Pharmacol.
353. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G. (2004). Antitumor activity
and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol
Cancer Ther 3, 233-244.
354. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. (2002). von Hippel
Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced
angiogenesis. FASEB J. 16, 264-266.
355. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H.
(2002). Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the
proteosome pathway in prostate cancer cells. Cancer Res 62, 2478-2482.
356. Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., and Katschinski, D.
M. (2005). Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90
inhibitors. Cancer Res 65, 11094-11100.
357. Erez, N., Milyavsky, M., Eilam, R., Shats, I., Goldfinger, N., and Rotter, V. (2003). Expression of
prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and
inhibits tumor growth. Cancer Res 63, 8777-8783.
358. D'Angelo, G., Duplan, E., Vigne, P., and Frelin, C. (2003). Cyclosporin A prevents the hypoxic
adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J Biol Chem. 278,
15406-15411.
359. Temes, E., Martin-Puig, S., Acosta-Iborra, B., Castellanos, M. C., Feijoo-Cuaresma, M., Olmos, G.,
Aragones, J., and Landazuri, M. O. (2005). Activation of HIF-prolyl hydroxylases by R59949, an
inhibitor of the diacylglycerol kinase. J Biol Chem. 280, 24238-24244.
360. Mie, L. Y., Kim, S. H., Kim, H. S., Jin, S. M., Nakajima, H., Jeong, K. H., and Kim, K. W. (2003).
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via
suppression of HIF-1alpha activity. Biochem Biophys.Res Commun. 300, 241-246.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
150
361. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S.,
Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W. (2001). Histone deacetylases induce
angiogenesis by negative regulation of tumor suppressor genes. Nat.Med. 7, 437-443.
362. Welsh, S. J., Williams, R. R., Birmingham, A., Newman, D. J., Kirkpatrick, D. L., and Powis, G.
(2003). The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit
Hypoxia-induced Factor 1{alpha} and Vascular Endothelial Growth Factor Formation. Mol Cancer
Ther 2, 235.
363. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. (1997).
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases
down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:
angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-
1530.
364. Chang, H., Shyu, K. G., Lee, C. C., Tsai, S. C., Wang, B. W., Hsien, L. Y., and Lin, S. (2003).
GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem Biophys.Res Commun.
302, 95-100.
365. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard,
M. T., Zhong, H., Simons, J. W., and Giannakakou, P. (2003). 2ME2 inhibits tumor growth and
angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375.
366. Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., and Van Waes, C. (2004). 2-
methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and
augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10,
8665-8673.
367. Cao, Z., Fang, J., Xia, C., Shi, X., and Jiang, B. H. (2004). trans-3,4,5'-Trihydroxystibene inhibits
hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian
cancer cells. Clin Cancer Res 10, 5253-5263.
368. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., and Park, J. W. (2003). YC-1: A
Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1. JNCI Cancer Spectrum 95, 516-
525.
369. Luwor, R. B., Lu, Y., Li, X., Mendelsohn, J., and Fan, Z. (2005). The antiepidermal growth factor
receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to
transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24, 4433-4441.
370. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S. W., and Shen, Y. (2005).
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA
interference in vivo. Cancer Res 65, 7249-7258.
371. Yoshimura, H., Dhar, D. K., Kohno, H., Kubota, H., Fujii, T., Ueda, S., Kinugasa, S., Tachibana, M.,
and Nagasue, N. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in
colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.
Clin Cancer Res 10, 8554-8560.
372. Covello, K. L., Simon, M. C., and Keith, B. (2005). Targeted Replacement of Hypoxia-Inducible
Factor-1{alpha} by a Hypoxia-Inducible Factor-2{alpha} Knock-in Allele Promotes Tumor Growth.
Cancer Res 65, 2277-2286.
373. Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D.,
Moreno-Murciano, M. P., Herbert, J. M., Burger, A., Riedel, J., Elvert, G., Flamme, I., Maxwell, P.
H., Collen, D., Dewerchin, M., Jain, R. K., Plate, K. H., and Carmeliet, P. (2005). Genetic evidence
for a tumor suppressor role of HIF-2alpha. Cancer Cell 8, 131-141.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
151
374. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002). Effect of p53 status on
tumor response to antiangiogenic therapy. Science 295, 1526-1528.
375. Allen, C. B., Schneider, B. K., and White, C. W. (2001). Limitations to oxygen diffusion and
equilibration in in vitro cell exposure systems in hyperoxia and hypoxia. Am.J.Physiol Lung Cell Mol
Physiol 281, L1021-L1027.
376. Kotelevets, L., van Hengel, J., Bruyneel, E., Mareel, M., van Roy, F., and Chastre, E. (2001). The
lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting
invasiveness. J.Cell Biol. 155, 1129-1136.
377. Subramanian, A. and Miller, D. M. (2000). Structural analysis of alpha-enolase. Mapping the
functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem. 275,
5958-5965.
378. Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S., and Imai, Y. (2001). Iba1 is an actin-cross-
linking protein in macrophages/microglia. Biochem Biophys.Res Commun. 286 , 292-297.
379. Mottet, D., Michel, G., Renard, P., Ninane, N., Raes, M., and Michiels, C. (2002). ERK and calcium
in activation of HIF-1. Ann.N.Y.Acad.Sci. 973, 448-453.
380. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M.
(2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Cancer Cell 3, 347-361.
381. Hayano, T. and Kikuchi, M. (1995). Cloning and sequencing of the cDNA encoding human P5.
Gene 164, 377-378.
382. Tanaka, S., Uehara, T., and Nomura, Y. (2000). Up-regulation of Protein-disulfide Isomerase in
Response to Hypoxia/Brain Ischemia and Its Protective Effect against Apoptotic Cell Death.
J.Biol.Chem. 275, 10388-10393.
383. Sakai, J., Ishikawa, H., Kojima, S., Satoh, H., Yamamoto, S., and Kanaoka, M. (2003). Proteomic
analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional
difference gel electrophoresis. Proteomics 3, 1318-1324.
384. Sullivan, D. C., Huminiecki, L., Moore, J. W., Boyle, J. J., Poulsom, R., Creamer, D., Barker, J., and
Bicknell, R. (2003). EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially
Expressed in Endothelial Cells Acts as a Stress Survival Factor. J.Biol.Chem. 278, 47079-47088.
385. Kivirikko, K. I. and Myllyharju, J. (1998). Prolyl 4-hydroxylases and their protein disulfide isomerase
subunit. Matrix Biol. 16, 357-368.
386. Lee, K. A., Shim, J. H., Kho, C. W., Park, S. G., Park, B. C., Kim, J. W., Lim, J. S., Choe, Y. K.,
Paik, S. G., and Yoon, D. Y. (2004). Protein profiling and identification of modulators regulated by
the E7 oncogene in the C33A cell line by proteomics and genomics. Proteomics 4, 839-848.
387. Ryu, J. W., Kim, H. J., Lee, Y. S., Myong, N. H., Hwang, C. H., Lee, G. S., and Yom, H. C. (2003).
The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 18, 505-509.
388. Chahed, K., Kabbage, M., Ehret-Sabatier, L., Lemaitre-Guillier, C., Remadi, S., Hoebeke, J., and
Chouchane, L. (2005). Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the
human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-
TOF-mass spectrometry analyses. Int J Oncol 27, 1425-1431.
389. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., and Li, D. (2004). Protein expression profiles in
pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by
pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer
Res 64, 9018-9026.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
152
390. Stierum, R., Gaspari, M., Dommels, Y., Ouatas, T., Pluk, H., Jespersen, S., Vogels, J., Verhoeckx,
K., Groten, J., and Ommen, B. v. (2003). Proteome analysis reveals novel proteins associated with
proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochimica et Biophysica
Acta (BBA) - Proteins & Proteomics 1650, 73-91.
391. Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M.,
Connor, J. R., Cherny, R. A., Volitakis, I., Bush, A., Langsetmo, I., Seeley, T., Gunzler, V., and
Ratan, R. R. (2005). HIF prolyl 4-hydroxylase inhibition: A target for neuroprotection in the central
nervous system. J Biol Chem.
392. Ghosh, A. K., Steele, R., and Ray, R. B. (2005). c-myc Promoter-binding protein 1 (MBP-1)
regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem. 280, 14325-14330.
393. Fan, X., Solomon, H., Schwarz, K., Kew, M. C., Ray, R. B., and Di Bisceglie, A. M. (2001).
Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in
cirrhosis and human hepatocellular carcinoma. Dig.Dis.Sci 46, 563-566.
394. Gerbitz, K. D., Summer, J., Schumacher, I., Arnold, H., Kraft, A., and Mross, K. (1986). Enolase
isoenzymes as tumour markers. J Clin Chem.Clin Biochem 24, 1009-1016.
395. Chang, Y. S., Wu, W., Walsh, G., Hong, W. K., and Mao, L. (2003). Enolase-alpha is frequently
down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin
Cancer Res 9, 3641-3644.
396. Wolf, D. H. and Hilt, W. (2004). The proteasome: a proteolytic nanomachine of cell regulation and
waste disposal. Biochim.Biophys.Acta 1695, 19-31.
397. Brahimi-Horn, C. and Pouyssegur, J. (2005). When hypoxia signalling meets the ubiquitin-
proteasomal pathway, new targets for cancer therapy. Critical Reviews in Oncology/Hematology 53,
115-123.
398. Mendoza, F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K., and Los, M. (2005). Anti-tumor
chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome
as targets. Arch.Immunol Ther Exp (Warsz.) 53, 47-60.
399. Okamura, T., Taniguchi, S., Ohkura, T., Yoshida, A., Shimizu, H., Sakai, M., Maeta, H., Fukui, H.,
Ueta, Y., Hisatome, I., and Shigemasa, C. (2003). Abnormally high expression of proteasome
activator-gamma in thyroid neoplasm. J Clin Endocrinol Metab 88, 1374-1383.
400. Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S.,
Shimbara, N., and Ichihara, A. (1991). Changes in expressions of proteasome and ubiquitin genes
in human renal cancer cells. Cancer Res 51, 6677-6685.
401. Khal, J., Hine, A. V., Fearon, K. C., Dejong, C. H., and Tisdale, M. J. (2005). Increased expression
of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell
Biol 37, 2196-2206.
402. Smith, H. J., Wyke, S. M., and Tisdale, M. J. (2004). Mechanism of the attenuation of proteolysis-
inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
Cancer Res 64, 8731-8735.
403. Hodgkinson, J. L., Peters, C., Kuznetsov, S. A., and Steffen, W. (2005). Three-dimensional
reconstruction of the dynactin complex by single-particle image analysis. Proc Natl Acad Sci U S A
102, 3667-3672.
404. Bhattacharya, N., Wang, Z., Davitt, C., McKenzie, I. F., Xing, P. X., and Magnuson, N. S. (2002).
Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111, 80-95.
405. Dammermann, A. and Merdes, A. (2002). Assembly of centrosomal proteins and microtubule
organization depends on PCM-1. J Cell Biol 159, 255-266.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
153
406. Corvi, R., Berger, N., Balczon, R., and Romeo, G. (2000). RET/PCM-1: a novel fusion gene in
papillary thyroid carcinoma. Oncogene 19, 4236-4242.
407. Sun, Q. Y. and Schatten, H. (2006). Role of NuMA in vertebrate cells: review of an intriguing
multifunctional protein. Front Biosci. 11, 1137-1146.
408. Tong, X., Xie, D., Roth, W., Reed, J., and Koeffler, H. P. (2003). NADE (p75NTR-associated cell
death executor) suppresses cellular growth in vivo. Int J Oncol 22, 1357-1362.
409. Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004). Hsp90-
binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem. 279,
22483-22489.
410. Burkhardt, J. K., Echeverri, C. J., Nilsson, T., and Vallee, R. B. (1997). Overexpression of the
dynamitin (p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of
membrane organelle distribution. J Cell Biol 139, 469-484.
411. Kondratova, A. A., Neznanov, N., Kondratov, R. V., and Gudkov, A. V. (2005). Poliovirus Protein 3A
Binds and Inactivates LIS1, Causing Block of Membrane Protein Trafficking and Deregulation of
Cell Division. Cell Cycle 4.
412. Valetti, C., Wetzel, D. M., Schrader, M., Hasbani, M. J., Gill, S. R., Kreis, T. E., and Schroer, T. A.
(1999). Role of dynactin in endocytic traffic: effects of dynamitin overexpression and colocalization
with CLIP-170. Mol Biol Cell 10, 4107-4120.
413. Clark, I. B. and Meyer, D. I. (1999). Overexpression of normal and mutant Arp1alpha (centractin)
differentially affects microtubule organization during mitosis and interphase. J Cell Sci 112 ( Pt 20), 3507-3518.
414. Deininger, M. H., Meyermann, R., and Schluesener, H. J. (2002). The allograft inflammatory factor-1
family of proteins. FEBS Lett. 514, 115-121.
415. Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., and Kohsaka, S. (1998). Microglia-specific
localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57, 1-9.
416. Ito, D., Tanaka, K., Suzuki, S., Dembo, T., and Fukuuchi, Y. (2001). Enhanced expression of Iba1,
ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain.
Stroke 32, 1208-1215.
417. Ohsawa, K., Imai, Y., Kanazawa, H., Sasaki, Y., and Kohsaka, S. (2000). Involvement of Iba1 in
membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci. 113 ( Pt 17), 3073-3084.
418. Imai, Y. and Kohsaka, S. (2002). Intracellular signaling in M-CSF-induced microglia activation: role
of Iba1. Glia 40, 164-174.
419. Ohsawa, K., Imai, Y., Sasaki, Y., and Kohsaka, S. (2004). Microglia/macrophage-specific protein
Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 88, 844-856.
420. Smith, I. F., Boyle, J. P., Vaughan, P. F., Pearson, H. A., and Peers, C. (2001). Effects of chronic
hypoxia on Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells.
J.Neurochem. 79, 877-884.
421. Berchner-Pfannschmidt, U., Petrat, F., Doege, K., Trinidad, B., Freitag, P., Metzen, E., de Groot, H.,
and Fandrey, J. (2004). Chelation of Cellular Calcium Modulates Hypoxia-inducible Gene
Expression through Activation of Hypoxia-inducible Factor-1{alpha}. J.Biol.Chem. 279, 44976-
44986.
422. Del Toro, R., Levitsky, K. L., Lopez-Barneo, J., and Chiara, M. D. (2003). Induction of T-type
Calcium Channel Gene Expression by Chronic Hypoxia. J.Biol.Chem. 278, 22316-22324.
Mecanismes de resposta a la inducció per hipòxia Bibliografia
154
423. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2004). Hypoxia upregulates von Hippel-Lindau
tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol
Renal Physiol 286, F338-F348.
424. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2003). HIF-1{alpha} mRNA and protein
upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci
116, 2247-2260.
425. Hirota, K. and Semenza, G. L. (2001). Rac1 Activity Is Required for the Activation of Hypoxia-
inducible Factor 1. J.Biol.Chem. 276, 21166-21172.
426. Xue, Y., Bi, F., Zhang, X., Pan, Y., Liu, N., Zheng, Y., and Fan, D. (2004). Inhibition of endothelial
cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells. Biochem
Biophys.Res Commun. 320, 1309-1315.
427. Udho, E., Tedesco, V. C., Zygmunt, A., and Krucher, N. A. (2002). PNUTS (phosphatase nuclear
targeting subunit) inhibits retinoblastoma-directed PP1 activity. Biochem Biophys.Res Commun.
297, 463-467.
428. Chen, J., Cohn, J. A., and Mandel, L. J. (1995). Dephosphorylation of ezrin as an early event in
renal microvillar breakdown and anoxic injury. Proc Natl Acad Sci U S A 92, 7495-7499.
429. Noda, Y., Horikawa, S., Katayama, Y., and Sasaki, S. (2005). Identification of a multiprotein "motor"
complex binding to water channel aquaporin-2. Biochem Biophys.Res Commun. 330, 1041-1047.
430. Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., and Verkman, A. S. (2005). Impairment of
angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434, 786-792.
431. Saadoun, S., Papadopoulos, M. C., Watanabe, H., Yan, D., Manley, G. T., and Verkman, A. S.
(2005). Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci
118, 5691-5698.